Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Anticonvulsants Stories

2013-12-06 00:20:48

SILVER SPRING, Md., Dec. 6, 2013 /PRNewswire-USNewswire/ -- A new white paper from the Tuberous Sclerosis Alliance (TS Alliance), entitled "Vigabatrin-Associated Visual Field Loss (VAVFL): What You Need to Know," was released today at the American Epilepsy Society annual meeting in Washington, DC. The white paper was written by Darcy A. Krueger, MD, PhD, Associate Professor, Clinical Pediatrics and Neurology, Tuberous Sclerosis Clinic, Cincinnati Children's Hospital. Vigabatrin is...

2013-12-05 08:29:48

WOODCLIFF LAKE, N.J., Dec. 5, 2013 /PRNewswire/ -- Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67(th) annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 - 10. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) "These data analyses highlight Eisai's clinical research with FYCOMPA, reinforcing our commitment to the epilepsy community," said Lynn Kramer,...

2013-12-02 23:27:25

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. Dallas, TX (PRWEB) December 02, 2013 The DrugNews.net prescription drug safety center is announcing the launch of a new resource for patients taking the antiepileptic drug Topamax. The site will contain studies on birth defect side effects, safety alerts for patients, as well as legal news for any birth defect claims. DrugNews is a...

2013-11-20 08:27:50

-- UCB-sponsored data include the first presentation of investigational data of VIMPAT® (lacosamide) as monotherapy for the treatment of partial-onset seizures in adults with epilepsy ATLANTA, Nov. 20, 2013 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at the 67th Annual Meeting of the American Epilepsy Society in Washington, D.C., December 6-10. The poster presentations on VIMPAT(®)...

2013-11-18 08:30:03

Multiple Presentations Highlight Findings from Phase 3 Trial Investigating USL255 for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures MAPLE GROVE, Minn., Nov. 18, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that it will present new research from its epilepsy clinical development program for USL255 (extended-release topiramate) during the American Epilepsy Society's (AES) 67(th) Annual Meeting in Washington, DC,...

2013-11-05 23:34:10

As Businessweek reported on October 30, a Philadelphia jury said that J&J's Janssen must pay $4 million in a lawsuit claiming that Topamax caused birth defects. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Topamax side effects. San Diego, CA (PRWEB) November 05, 2013 AttorneyOne.com, a recognized authority on law, updated the...

2013-11-05 08:36:28

Multiple Presentations Highlight Progress of Epilepsy Program MAPLE GROVE, Minn., Nov. 5, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that seven abstracts highlighting results from its Phase 3 (PREVAIL) clinical trial for USL255 (extended-release topiramate) have been accepted for presentation at the American Epilepsy Society's (AES) 67(th) Annual Meeting in Washington, DC, December 6-10, 2013. (Logo:...

2013-11-04 10:36:26

Bipolar drugs lose effect during pregnancy, so women need higher doses to stay well New Northwestern Medicine® research offers one of the first in-depth studies of how physiological changes during pregnancy reduce the effects of a commonly used drug to treat bipolar disorder, making women more vulnerable to recurring episodes. The new findings will help psychiatrists and physicians prevent bipolar manic and depressive symptoms during pregnancy, which are risky for the health of the mother...

2013-11-04 08:25:48

- Results from VIMPAT® (lacosamide) monotherapy study supporting this filing to be presented at AES 2013 ATLANTA, Nov. 4, 2013 /PRNewswire/ -- UCB announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental new drug application (sNDA) for VIMPAT(®) (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. Investigational data from the phase 3 lacosamide conversion to monotherapy study in...

2013-11-01 10:46:34

50 years after valproate was first discovered, research published today in the journal Neurobiology of Disease, reports how the drug works to block seizure progression. Valproate (variously labelled worldwide as Epilim, Depacon, Depakene, Depakote, Orlept, Episenta, Orfiril, and Convulex) is one of the world's most highly prescribed treatments for epilepsy. It was first discovered to be an effective treatment for epilepsy, by accident, in 1963 by a group of French scientists. In...